Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

Affiliations

• ¹ Department of Surgery and Cancer, Imperial College London, London, UK. c.coombes@imperial.ac.uk.
• ² Department of Surgery and Cancer, Imperial College London, London, UK.
• ³ Cancer Research UK Clinical Trials Unit, Beatson West of Scotland Cancer Centre, Glasgow, UK.
• ⁴ Medical Oncology, Addenbrooke's Hospital, Breast Cancer Research Unit, Cancer Research UK Cambridge Centre, Cambridge, UK.
• ⁵ Sir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care, Freeman Hospital, Newcastle, UK.
• ⁶ Breast Research Office, The Christie NHS Foundation Trust, Christie Hospital, Manchester, UK.
• ⁷ C8 Admin Offices, Russell's Hall Hospital, Russells Hall, UK.
• ⁸ Astrazeneca, Cheshire, UK.
• ⁹ ECMC Programme Office, Research and Innovation, Cancer Research UK, London, UK.
• ¹⁰ Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
• ¹¹ Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Pathology, Cancer Centre Amsterdam, Amsterdam, The Netherlands.
• ¹² Department of Surgery and Cancer, Imperial College London, London, UK. m.seckl@imperial.ac.uk.